Mechanism of action of beta-blocking agents in heart failure
Mechanism of action of beta-blocking agents in heart failure
复制标题
DOI：
10.1016/s0002-9149(97)00846-1
复制
发表时间：
1997-12-04
影响因子：
2.8
通讯作者：
Bristow, MR
中科院分区：
文献类型：
--
作者：
Bristow, MR
抗肾上腺素能治疗是目前治疗慢性心力衰竭的新兴且非常有前途的方法，尽管肾上腺素能神经系统可以在多个水平上被抑制，但受体阻断剂的使用产生了最大的兴趣，并为该方法的“概念证明”提供了最多的数据，部分原因是慢性心力衰竭的抗肾上腺素能治疗是在最初被认为是禁忌的环境中发展起来的（即，在III期临床试验开始之前），需要大量的假设驱动的基础和临床研究来定义总体原理并证明可行性，本文将回顾这些数据并提出一个单一的主要作用机制来解释这些药物的大部分临床益处。(C)1997年，Excerpta Medica，Inc.
Antiadrenergic treatment is currently an emerging and very promising approach to the treatment of chronic heart failure, Although the adrenergic nervous system can be pharmacologically inhibited at multiple levels, it is the use of receptor-blocking agents that has generated the most interest and provided the most data for the ''proof of concept'' of this approach, In part because antiadrenergic treatment of chronic heart failure has developed in an atmosphere in which it was initially considered to be contraindicated (i.e., before Phase III clinical trials could be initiated), a large body of hypothesis-driven basic and clinical investigation was required to define the overall rationale and demonstrate feasibility, This article will review these data and propose a single primary mechanism of action to explain most of the clinical benefits of these agents. (C) 1997 by Excerpta Medica, Inc.